Adage Capital Partners’s Arbutus Biopharma ABUS Stock Holding History

Adage Capital Partners’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,664,941	Closed	-$12M	–	1003
2026 Q1	$12M	Sell	2,664,941 -1,675,000	-39%	-$7.32M	0.02%	645
2025 Q4	$20.9M	Sell	4,339,941 -675,000	-13%	-$3.04M	0.03%	469
2025 Q3	$22.8M	Buy	5,014,941 +2,439,000	+95%	+$8.96M	0.04%	425
2025 Q2	$7.96M	Buy	2,575,941 +1,000,000	+63%	+$3.32M	0.01%	654
2025 Q1	$5.5M	Sell	1,575,941 -75,000	-5%	-$250K	0.01%	685
2024 Q4	$5.4M	Sell	1,650,941 -1,250,000	-43%	-$4.6M	0.01%	710
2024 Q3	$11.2M	Sell	2,900,941 -99,059	-3%	-$380K	0.02%	586
2024 Q2	$9.27M	Hold	3,000,000	–	–	0.02%	618
2024 Q1	$7.74M	Buy	+3,000,000	New	+$7.77M	0.01%	643

Other funds holding ABUS

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Adage Capital Partners's ABUS Position: Q2 2026 in Review

Adage Capital Partners sold out of Arbutus Biopharma (ABUS) in Q2 2026, closing a stake of 2,664,941 shares — an estimated $12M sold.

Adage Capital Partners first reported a position in ABUS in Q1 2024 and held it in 9 quarters. The position peaked at $22.8M in Q3 2025. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

Adage Capital Partners reported no remaining Arbutus Biopharma position as of Q2 2026 after selling out during the quarter.
Adage Capital Partners sold 2,664,941 Arbutus Biopharma shares in Q2 2026, an estimated $12M.
Adage Capital Partners first reported a position in Arbutus Biopharma in Q1 2024 and held it in 9 quarters.
Adage Capital Partners's Arbutus Biopharma position peaked at $22.8M in Q3 2025.
176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.